Keywords:
Cancer, Outcomes analysis, Ultrasound, Mammography, Breast, Outcomes
Authors:
P. Saenz1, S. Carrillo1, D. Timaran2, J. Orozco Vazquez1, M. D. R. Garcia1; 1Mexico City/MX, 2Mexico, Me/MX
DOI:
10.26044/ecr2019/C-1842
Results
The study included a total of 591 patients with BI-RADS lesions.
Among them,
322 (55%) continued with short-term follow,
as recommended.
Total population included 321 (99.7%)women and 1 man.
The median age of the cohort was 54 years (interquartile range [IQR],
48-62 years).
At a median time of 8 months (IQR,
6-13 months) imaging evaluation that included mammography and ultrasound was performed.
In total,
242 (68%) were re classified as BI-RADS 2,
80 (22%) persisted with BI-RADS 3,
and 37 (10%) were classified as BI-RADS 4 (Figure 4).
All patients with BI-RADS 4 lesions and 3 (0.9%) with B-IRADS 3 underwent biopsy under ultrasound (55%) and stereotactic guidance (45%) after BI-RADS re classification.
After histologic assessment,
14 malignant lesions were reported,
13 (93%) were invasive cancers and one was ductal carcinoma in situ (7%).
Among them,
7 patients (50%) had personal history of breast cancer and 9 (64%) had family history of breast cancer (p=0.1) (Figure 5).
Personal history of other malignancies was present in 25% (p>0.1)(Figure 6).
All patients re classified to BIRADS 2 at re-assessment visit remained stable during the review period and continued follow-up annually as recommended by guidelines.
Patients that remained with BIRADS 3 at end of the study were scheduled for imaging assessment at 6 months.